CollPlant Biotechnologies LtdCLGN
Price$3.57Intrinsic value$3.502% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $2.4M+360.4% YoYTTM through 31 Dec 2025
Net Income -$11.5MTTM through 31 Dec 2025
Free Cash Flow -$9.4MTTM through 31 Dec 2025

Margins

Current
Gross Margin64.8%
EBITDA Margin-445.8%
Operating Margin-484.3%
Net Margin-484.6%

Returns

-188.9%ROE
-106.5%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio2.53x
Net Debt-$5.6Mnet cash position
Cash & Equivalents$5.6M

Quality Metrics

Altman Z-Score-18.12
Piotroski F-Score4 / 9
FCF Margin-398.4%
Earnings-Beat Rate0.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $2.4M
Diluted EPS-$0.94TTM
'19'20'21'22'23'24'25
FY2025: $-0.94

Dividend

No dividend

Capital Allocation

Capex Intensity1.2%

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.